PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
SYCUME ® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN ...
2026-10-09T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Telix to Host Capital Markets Day in Melbourne on November 4, 2026
MELBOURNE, Australia and INDIANAPOLIS , Oct. 9, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announced that it will host a Capital Markets Day in ...
2026-10-09T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
GenScript Launches Life Sciences Startup PitchFest with NVIDIA to Accelerate Biotech Innovation
Inaugural competition will connect emerging AI life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week ...
2026-10-08T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Wellysis Secures FDA 510(k) Clearance for AI-Powered ECG Analysis Software, S-Patch CardioAI
Adds FDA-cleared AI analysis to Wellysis' S-Patch ECG monitoring solution, expanding its capabilities beyond ECG acquisition Enables FDA-cleared AI analysis of S-Patch ECG data to be integrated into ...
2026-10-08T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering
TAIZHOU, China , Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain ...
2026-10-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
SECuRE update: recruitment target of the Cohort Expansion Main Group achieved
SYDNEY , Oct. 8, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation ...
2026-10-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON , Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS  (NASDAQ: SOPH) and Myriad Genetics, Inc. , (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic ...
2026-10-08T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Helfie Signs MOU with Homa Bay Kenya Ministry of Health for TB and Hypertension Screening Pilot
Population-scale pilot will target 100,000 of Homa Bay's most vulnerable people  across five sub-counties. ...
2026-10-08T    Computer/Electronics   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Rockwell Automation and Industry Leaders Launch the Digital CMC Consortium to Accelerate Digital Transformation in Pharmaceutical Development
New industry collaboration addresses pharma's most complex development challenges and expedites patient access to breakthrough therapies ...
2026-10-08T    Chemical   Computer/Electronics   Health Care/Hospital 
MAYBELLINE NEW YORK LAUNCHES "TOGETHER WE'RE BRAVE" CAMPAIGN FOR WORLD MENTAL HEALTH DAY
Maybelline's Brave Together Platform Introduces New Campaign That Spotlights the Power of Connection and Support in Mental Health Journeys ...
2026-10-08T    Cosmetics & Personal Care   Health Care/Hospital   Household/Consumer/Cosmetics   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.